Jupiter Asset Management Ltd. Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Jupiter Asset Management Ltd. boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 589.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 746,509 shares of the biopharmaceutical company's stock after purchasing an additional 638,259 shares during the quarter. Jupiter Asset Management Ltd.'s holdings in Pfizer were worth $19,805,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $26,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $28,000. Finally, Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the 4th quarter worth $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on PFE shares. Bank of America restated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Wednesday. StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Finally, Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $31.92.

Remove Ads

Pfizer Price Performance

NYSE PFE opened at $25.73 on Thursday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $145.79 billion, a PE ratio of 18.24, a P/E/G ratio of 0.64 and a beta of 0.61. The company's 50 day simple moving average is $26.28 and its 200 day simple moving average is $27.18.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company posted $0.10 EPS. The company's revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.